Últimas noticias sobre Evaxion Biotech (NASDAQ:EVAX) Bolsa

Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

IDAI

INTZ

LIDR

LKCO

LUXH

MGIH

MLGO

MRBK

MTRX

NEUP

ONDS

QRHC

RVSN

SLDP

VIRX

WTBA

Descubre las acciones que lideran los movimientos en la apertura del mercado, incluyendo repuntes destacados y caídas sorprendentes.

Acciones de Evaxion Biotech (EVAX) suben alrededor del 62%; 20 acciones que se mueven en el premercado

Long Ideas

AREN

CSTM

GDYN

GEAR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: CSTM, VIRX, EVAX, AREN y GDYN.

5 acciones en el foco este viernes: CSTM, VIRX, EVAX, AREN y GDYN

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech AS

Tiziana Life Sciences, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. This pivotal step marks a significant advancement in the company's commitment to advance a new treatment approach for Amyotrophic Lateral Sclerosis (ALS) which is supported by the ALS Association.
This IND filing follows the prestigious award of a grant as part of the Hoffman ALS Clinical Trial Awards Program from the ALS Association. Tiziana's intranasal foralumab development programs are now focused on 3 neurodegenerative diseases. ALS, Multiple Sclerosis, and Alzheimer's disease. This grant provides a framework for industry-academia collaboration where new discoveries are translated to clinical studies through innovative research and development.
ALS, also known as Lou Gehrig's disease is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its clinical course can be rapid with marked disability even at an early stage. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. The disease is always fatal, usually within five years of diagnosis. Despite its devastating impact, treatment options remain limited, highlighting the critical importance of advancing research efforts like those undertaken by Tiziana Life Sciences.
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant. This filing represents a significant achievement for our team and underscores our commitment to addressing the urgent medical needs of ALS patients."
Upon FDA clearance of the IND application, Tiziana plans to commence a 20-patient clinical trial of two doses of Tiziana's novel and patented therapeutic candidate, intranasal foralumab, aimed at evaluating the safety and early-stage parameters of disease improvement in Amyotrophic Lateral Sclerosis (ALS). The company remains dedicated to delivering innovative solutions that can potentially improve outcomes and quality of life for ALS patients worldwide.

Biotech

General

TLSA

Tiziana Life Sciences Announces Investigational New Drug Application Submission For Phase 2 Trial Of Intranasal Foralumab In ALS, Supported By ALS Association

- STAR-1 topline results expected by the end of March 2025 -
- Over 30 million acne patients seek treatment in the U.S. each year -
- XYNGARI&#x2122; Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S.&nbsp; and Latin America -

DRMA

Dermata Announced Last Patient Completed Last Visit In XYNGARI Phase 3 STAR-1 Clinical Trial For Acne

New controlled study published in&nbsp;Journal of Nutrition and Dietary Supplements highlights statistically significant reductions in ethanol levels following acute alcohol intake
SCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or the "Company"), a wellness and dietary supplement company, today announces the peer-reviewed publication of its groundbreaking randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy of Safety Shot&#xAE; in mitigating the negative effects of alcohol consumption. The study, published in the Journal of Nutrition and Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62), demonstrates that Safety Shot&#xAE; statistically significantly reduces blood alcohol concentration (BAC), breath alcohol concentration (BrAC), and hangover symptoms compared to placebo (p &lt; 0.05), and at a remarkably faster rate than the body's natural processes. For the complete article, visit the website at: <a href="https://www.globenewswire.com/Tracker?data=WMrB5FCJ7spqdDFaiGgaOalIPHMLw7p7IOTyw0oAzKQ3WxqFYU0LFhPAP0b-gLXh5BNsAX0_KrPK6x9IyWGObFFPAF2q9v4zTdH-7dHHILiW1TDVIt0rcNZlwME-V15r">https://doi.org/10.2147/NDS.S507571</a>

SHOT

Safety Shot Announces First Peer-Reviewed Publication Of Human Clinical Trial Confirming Rapid Alcohol Reduction And Hangover Prevention Published In The Journal Of Nutrition And Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62)

Mizuho analyst Vijay Rakesh maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Outperform and raises the price target from $58 to $68.

Price Target

Analyst Ratings

MCHP

Mizuho Maintains Outperform on Microchip Technology, Raises Price Target to $68

WIIM

MASS

908 Devices shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS and revenue estimates.

Management

BCRX

BioCryst Pharmaceuticals' CFO Anthony Doyle Notified The Company Of His Intention To Resign From His Employment With The Company, Effective April 9, 2025

ALZN

Alzamend Neuro Plans To Initiate Phase II Study Of AL001 In Bipolar Disorder, Expected To Commence In Q3

&nbsp;ServiceNow and DXC expand their strategic partnership to combine DXC's industry-leading software and expertise with ServiceNow's AI-enabled platform
ASHBURN, Va. and SANTA CLARA, Calif., March 4, 2025 /PRNewswire/ -&nbsp;DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>), a leading Fortune 500 global technology services provider, today announced new offerings with ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), the AI platform for business transformation, to modernize the insurance industry. As an Elite partner, DXC is combining its <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4374637-1&amp;h=7510929&amp;u=https%3A%2F%2Fdxc.com%2Fus%2Fen%2Fabout-us%2Fawards-and-recognition%2Fdxc-technology-is-recognized-by-everest-group-as-the-leading-life-and-annuities-insurance-technology-provider-is-everest-groups-inaugural-ranking&amp;a=industry-leading+solutions">industry-leading solutions</a>&nbsp;and ServiceNow's AI capabilities&nbsp;and workflows&nbsp;to introduce DXC Assure BPM (Business Process Management) powered by ServiceNow.
Today's insurers are&nbsp;pressured to accelerate growth and innovation, streamline operations, and provide faster, more reliable services to policyholders, but are often constrained by processes and workflows that are complex and highly manual. According to HFS&nbsp;Research, 45% of insurers are already investing in technology-driven alignment of their front, middle, and back offices.
DXC and ServiceNow are uniquely positioned to help insurers drive innovation for greater operational efficiency.&nbsp;&nbsp;Combining DXC's insurance expertise and scale with ServiceNow's single platform and data model, DXC Assure BPM powered by ServiceNow integrates AI, data and workflows to reduce process debt, enhance operational efficiency, and improve customer satisfaction. The solution applies across the entire policy lifecycle and is expected to help reduce up to 40% of operational costs typically spent on manual processing.

DXC And ServiceNow Announce New Offerings To Drive AI-Powered Innovation For The Insurance Industry

Contracts

UAVS

AgEagle Aerial Systems Fulfilled Previously Announced Order For 60 RedEdge-P Multispectral Sensors

BOOM

DynaEnergetics Announces It Will Institute A Tariff Surcharge Ranging From 7% To 9% On All Perforating Systems Sold in North America, Effective April 5, 2025. The Surcharge Is Being Implemented In Response To Higher Raw Material Costs Resulting From U.S. Tariffs

ILMN

Illumina shares are trading lower after China banned its gene sequencer imports.

Village Super Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLGEA#NASDAQ">VLGEA</a>) reported quarterly earnings of $1.14 per share. This is a 17.53 percent increase over earnings of $0.97 per share from the same period last year. The company reported $599.65 million in sales this quarter. This is a 4.18 percent increase over sales of $575.58 million the same period last year.

Earnings

VLGEA

Village Super Market Q2 EPS $1.14 Up From $0.97 YoY, Sales $599.65M Up From $575.58M YoY

NYAX

Nayax shares are trading lower after the company reported worse-than-expected Q4 financial results.

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">43.60</td>
<td align="right">0.08</td>
<td align="right">0.18</td>
<td>5.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">83.63</td>
<td align="right">0.11</td>
<td align="right">0.13</td>
<td>13.6K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">216.57</td>
<td align="right">-2.10</td>
<td align="right">-0.97</td>
<td>39.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">210.11</td>
<td align="right">-1.87</td>
<td align="right">-0.89</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">87.08</td>
<td align="right">-0.74</td>
<td align="right">-0.85</td>
<td>157.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.47</td>
<td align="right">-0.27</td>
<td align="right">-0.53</td>
<td>326.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">133.75</td>
<td align="right">-0.64</td>
<td align="right">-0.48</td>
<td>389</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">149.40</td>
<td align="right">-0.18</td>
<td align="right">-0.13</td>
<td>2.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">86.90</td>
<td align="right">-0.08</td>
<td align="right">-0.10</td>
<td>465</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">79.30</td>
<td align="right">-0.03</td>
<td align="right">-0.04</td>
<td>5.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For March 4, 2025

Mizuho analyst Gregg Moskowitz upgrades Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Neutral to Outperform and raises the price target from $110 to $127.

Upgrades

OKTA

Mizuho Upgrades Okta to Outperform, Raises Price Target to $127

OLPX

Olaplex Holdings shares are trading higher after the company reported better-than-expected Q4 revenue results and issued FY25 sales guidance above estimates.

Earnings Beats

QXO Q4 2024 GAAP EPS $(0.02), Sales $14.743M Beat $14.000M Estimate

Eric Trump's recent comments on the <a href="https://www.benzinga.com/25/03/44087250/strategys-saylor-calls-crypto-reserve-bullish-for-bitcoin-predicts-100-trillion-opportunity">strategic crypto reserve announcement</a> have sparked mixed reactions, with some praising him while others criticize the Trump family&#8217;s involvement in the industry.
What Happened: In an <a href="https://x.com/EricTrump/status/1896552942838350001">X</a> post on Monday, Eric Trump expressed gratitude after popular crypto trader AltcoinGordon credited his late-February &#8220;buy the dips&#8221; advice when Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dropped below $90,000 on Feb. 25. 
Gordon tweeted, "Never fade Eric Trump," to which Trump responded by saying he's happy he could help and recommends investors to hold for the long term.
His post triggered a variety of reactions from the crypto community.
Michael Saylor echoed the sentiment, simply posting "HODL," while industry expert Quinten Francois warned to not bet against the Trump family.
Influencer Ted Pillows questioned if Trump was suggesting holding even through losses and jokingly proposed a Friday announcement to trigger a 500% rally.        
Economist Peter Schiff <a href="https://x.com/PeterSchiff/status/1896637889687204155">slammed</a> Trump's so-called &#8220;genius&#8221; Sunday announcement, arguing there was no formal agreement on a strategic reserve. 
He called it a pump and dump, suggesting the timing was intentional to maximize impact when trading volume was thin.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44080002/crypto-czar-david-sacks-confirms-selling-all-bitcoin-ethereum-solana-holdings-denies-large-indirect-holdings">Crypto Czar David Sacks Confirms Selling All Bitcoin, Ethereum, Solana Holdings, Denies &#8216;Large Indirect Holdings&#8217;</a>
What's Next: In another <a href="https://x.com/PeterSchiff/status/1896687148516221227">X</a> post, Schiff specifically called out Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) performance following Trump's so-called "Truth Social Sunday Ethereum pump." 
He pointed out that ETH ETFs are at record lows, down 40% from their launch about eight months ago and 49% below their December 2023 highs.
Schiff predicted that Ethereum still has significant downside ahead, warning investors of further declines.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44085332/peter-schiff-says-trump-forcing-us-taxpayers-to-buy-bitcoin-and-other-worthless-crypto-is-preventing-the-market-from-collapse">Peter Schiff Says Trump Forcing US Taxpayers To Buy Bitcoin &#8216;And Other Worthless Crypto&#8217; Is Preventing The Market From Collapse</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Eric Trump Said 'Buy The Dips' In February, But Peter Schiff Isn't Buying The 'Genius' Bitcoin, XRP, Cardano Strategic Reserve Announcement

PEPG

PepGen To Temporarily Pause CONNECT2-EDO51 Study And Focus Efforts On CONNECT1-EDO51 Study Of PGN-EDO51 In DMD

ABBV

AbbVie Announces SKYRIZI Available In Canada For Treatment Of Ulcerative Colitis Following Health Canada Approval

Press Releases

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Evaxion announces completion of ADS ratio change

Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Evaxion announces pricing of $10.8 million public offering

Evaxion announces closing of $10.8 million public offering

Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges – More Stocks Inside

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Comments

Evaxion Biotech

Noticias

Últimas noticias sobre Evaxion Biotech (NASDAQ:EVAX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL